InsideTracker, which considers itself the leading health span optimization platform, has raised $15 million in Series B funding to drive continued innovation and delivery of its AI platform for personalized nutrition and health span optimization. The app analyzes blood and DNA tests, wearables and demographic information in addition to the diet, longevity and chronic disease database to make tailored lifestyle recommendations.
The round was led by PeakBridge with the participation of Cornucopian Capital, BASF VC and OurCrowd, with the participation of Cornucopian Capital and OurCrowd and the continued support of existing investors. The announcement marks the first time InsideTracker’s 3-year relationship with BASF VC has been disclosed.
The latest funding round follows the exponential growth in sales of InsideTracker’s precision wellness system for personalized nutrition and health span optimization. The healthspan optimizer integrates biomarker data from blood, DNA, activity trackers and user-generated demographic information to provide science-based recommendations to optimize healthspan.
“This new investment will enable us to enhance research and development efforts, expand marketing and support operations to deliver our solutions to help people around the world live healthier and longer lives,”said Rony Sellam, CEO of InsideTracker.
Powered by a proprietary AI engine, InsideTracker combines machine learning and computational biology with over 60,000 man-hours of meta-analysis and curation from its multidisciplinary team of scientists and subject matter experts. Ongoing engine research, development and calibration is led by Renee Deehan, PhD, Vice President of Science and Artificial Intelligence; Gil Blander, PhD, Founder and Chief Scientific Officer; and a team of renowned Scientific Advisory Board members, including recent additions Eran Segal, PhD, and Ali Torkamani, PhD.